Advice
Following a full submission
pegylated liposomal doxorubicin (Caelyx®) is not recommended for use within NHS Scotland in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.
Results from an interim analysis showed that pegylated liposomal doxorubicin plus bortezomib significantly increased the time to progression compared to bortezomib monotherapy. At the time of the interim analysis only 31% of patients in the combination arm had reached the primary endpoint.
The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice69KB (PDF)
Medicine details
- Medicine name:
- pegylated liposomal doxorubicin (Caelyx)
- SMC ID:
- 503/08
- Indication:
- Progressive multiple myeloma in patients who have received at least one prior therapy
- Pharmaceutical company
- Schering-Plough Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 13 October 2008